NeutroSpec Promos Tout Broad, Unsupported Indications, FDA Chides
This article was originally published in The Pink Sheet Daily
The withdrawn imaging agent is cited for violations made during the 2005 American Pharmaceutical Association annual meeting.
You may also be interested in...
FDA "reconsidered" the risk/benefit balance for Mallinckrodt/Palatin Technologies' appendicitis imaging agent, which has been associated with cardiopulmonary events.
Revlimid, Copaxone, Sensipar, Enbrel, Acthar Gel and Gleevec will be the subject of a US House Committee on Oversight and Reform in an upcoming drug price hearing.
Pfizer was heavily invested in immuno-oncology combinations five years ago, but following setbacks, the pipeline has shifted considerably, shaped partly by the acquisition of Array.